<DOC>
	<DOC>NCT01050283</DOC>
	<brief_summary>This study will determine whether [18F]-fluorodeoxyglucose-positron emission tomography (FDG-PET) can be used to screen for the activity of novel pancreatic cancer treatments.</brief_summary>
	<brief_title>A Study to Evaluate [18F]-FDG PET (Fluorodeoxyglucose-positron) in Patients With Pancreatic Cancer (MK-0000-144)</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<criteria>Patient has a diagnosis of Stage IV pancreatic adenocarcinoma with distant metastases Patient is scheduled to receive standard chemotherapy containing gemcitabine Patient has not received prior systemic therapy for advanced pancreatic adenocarcinoma Patient must be available for periodic blood sampling, studyrelated assessments, and management at the treating institution Patient has had open abdominal surgery within 6 weeks of the screening visit Patient has had radiotherapy to the thorax, abdomen, or pelvis within 6 months of the screening visit Patient has an active infection, inflammation, or unresolved bowel obstruction Patient has poorly controlled diabetes</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Advanced pancreatic adenocarcinoma</keyword>
</DOC>